Combination therapy in dyslipidemia: Where are we now?

Alberico L. Catapano; Michel Farnier; JoAnne M. Foody; Peter P. Toth; Joanne E. Tomassini; Philippe Brudi; Andrew M. Tershakovec

doi:10.1016/j.atherosclerosis.2014.09.026

Combination therapy in dyslipidemia: Where are we now?

Alberico L. Catapano, Michel Farnier, JoAnne M. Foody, Peter P. Toth, Joanne E. Tomassini, Philippe Brudi, Andrew M. Tershakovec

IRCCS Multimedica

Research output: Contribution to journal › Article › peer-review

Abstract

Lowering low-density lipoprotein cholesterol (LDL-C) reduces the risk of cardiovascular disease: each 1.0mmol/L (38.7mg/dL) reduction in LDL-C reduces the incidence of major coronary events, coronary revascularizations, and ischemic stroke by approximately 20%. Statins are a well-established treatment option for dyslipidemia, with LDL-C reduction in the range of 27-55%.Several lipid goal-driven guidelines recommend reducing LDL-C to

Original language	English
Pages (from-to)	319-335
Number of pages	17
Journal	Atherosclerosis
Volume	237
Issue number	1
DOIs	https://doi.org/10.1016/j.atherosclerosis.2014.09.026
Publication status	Published - Nov 1 2014

Keywords

Combination therapy
Ezetimibe
Fibrate
LDL-C
Niacin
PCSK9
Statin

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine
Medicine(all)

Access to Document

10.1016/j.atherosclerosis.2014.09.026

Cite this

@article{7140ff268c104cfb8634f675eea68631,

title = "Combination therapy in dyslipidemia: Where are we now?",

abstract = "Lowering low-density lipoprotein cholesterol (LDL-C) reduces the risk of cardiovascular disease: each 1.0mmol/L (38.7mg/dL) reduction in LDL-C reduces the incidence of major coronary events, coronary revascularizations, and ischemic stroke by approximately 20%. Statins are a well-established treatment option for dyslipidemia, with LDL-C reduction in the range of 27-55%.Several lipid goal-driven guidelines recommend reducing LDL-C to ",

keywords = "Combination therapy, Ezetimibe, Fibrate, LDL-C, Niacin, PCSK9, Statin",

author = "Catapano, {Alberico L.} and Michel Farnier and Foody, {JoAnne M.} and Toth, {Peter P.} and Tomassini, {Joanne E.} and Philippe Brudi and Tershakovec, {Andrew M.}",

year = "2014",

month = nov,

day = "1",

doi = "10.1016/j.atherosclerosis.2014.09.026",

language = "English",

volume = "237",

pages = "319--335",

journal = "Atherosclerosis",

issn = "0021-9150",

publisher = "Elsevier Ireland Ltd",

number = "1",

}

TY - JOUR

T1 - Combination therapy in dyslipidemia

T2 - Where are we now?

AU - Catapano, Alberico L.

AU - Farnier, Michel

AU - Foody, JoAnne M.

AU - Toth, Peter P.

AU - Tomassini, Joanne E.

AU - Brudi, Philippe

AU - Tershakovec, Andrew M.

PY - 2014/11/1

Y1 - 2014/11/1

N2 - Lowering low-density lipoprotein cholesterol (LDL-C) reduces the risk of cardiovascular disease: each 1.0mmol/L (38.7mg/dL) reduction in LDL-C reduces the incidence of major coronary events, coronary revascularizations, and ischemic stroke by approximately 20%. Statins are a well-established treatment option for dyslipidemia, with LDL-C reduction in the range of 27-55%.Several lipid goal-driven guidelines recommend reducing LDL-C to

AB - Lowering low-density lipoprotein cholesterol (LDL-C) reduces the risk of cardiovascular disease: each 1.0mmol/L (38.7mg/dL) reduction in LDL-C reduces the incidence of major coronary events, coronary revascularizations, and ischemic stroke by approximately 20%. Statins are a well-established treatment option for dyslipidemia, with LDL-C reduction in the range of 27-55%.Several lipid goal-driven guidelines recommend reducing LDL-C to

KW - Combination therapy

KW - Ezetimibe

KW - Fibrate

KW - LDL-C

KW - Niacin

KW - PCSK9

KW - Statin

UR - http://www.scopus.com/inward/record.url?scp=84907979645&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907979645&partnerID=8YFLogxK

U2 - 10.1016/j.atherosclerosis.2014.09.026

DO - 10.1016/j.atherosclerosis.2014.09.026

M3 - Article

C2 - 25299967

AN - SCOPUS:84907979645

SN - 0021-9150

VL - 237

SP - 319

EP - 335

JO - Atherosclerosis

JF - Atherosclerosis

IS - 1

ER -

Combination therapy in dyslipidemia: Where are we now?

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this